Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.
J Clin Endocrinol Metab
; 107(7): 1888-1896, 2022 06 16.
Article
in En
| MEDLINE
| ID: mdl-35397165
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Diabetes Mellitus, Type 2
/
Gastrointestinal Microbiome
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
J Clin Endocrinol Metab
Year:
2022
Document type:
Article
Affiliation country:
China
Country of publication:
United States